Date: 2015-05-19
Type of information: Nomination
Compound:
Company: Intarcia Therapeutics (USA - CA)
Therapeutic area: Metabolic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On May 19, 2015, Intarcia Therapeutics announced the appointment of Emad Rizk, MD to its Board of Directors. Dr. Rizk is a well-respected leader in the healthcare industry, and an expert on payers and healthcare economics. He joins the Intarcia Board as the Company nears completion of its clinical development for ITCA 650 (a once- or twice-yearly continuous subcutaneous delivery of exenatide), its lead therapeutic candidate for the treatment of type 2 diabetes. Dr. Rizk currently serves as President and Chief Executive Officer of Accretive Health, a company committed to partnering with healthcare Providers. He previously served as President of McKesson Health Solutions, a business unit of McKesson Corporation, and as Senior Partner and Global Director, Medical Management/Pharmacy for Deloitte Consulting, leading the company’s medical cost and quality management practice. Previous to that, he held a variety of roles at Monsanto Corporation, serving as Associate Medical Director, Corporate Medical and Scientific Affairs and then Worldwide Medical Director.
Dr. Rizk was formerly a member of the board of DMAA: Care Continuum Alliance and currently serves on the boards of directors of the National Association for Hispanic Health, Manage Care Editorial, Accuray Inc. and Accretive Health. A Senior Scholar professor at Jefferson Medical College, Dr. Rizk’s work has been widely published in medical journals and medical books. His book, The New Era of Healthcare: Practical Strategies for Providers and Payers, focuses on ways that providers and payers can work together to reduce costs while improving efficiency and patient care.
Financial terms:
Latest news:
